在ADHD中GABAergic功能障碍的新药学标
Anthony S Ferranti1, Deborah J Luessen1, Colleen M Niswender2
1Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA; Warren Center for Neuroscience Drug Discovery, Nashville, TN, 37232, USA.
注意缺陷/多动障碍 (ADHD) 涉及到大脑激发和抑制的不平衡. GABAergic功能障碍越来越多地涉及,提供了超越传统兴奋剂的ADHD治疗的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 遗传学 是一个遗传学.
背景情况:
- 注意缺陷/多动障碍 (ADHD) 影响约5%的人口,其特点是冲动性,多动性和注意力缺陷.
- 目前用于ADHD的兴奋剂治疗向多巴胺基信号,但对近三分之一的患者无效,并有不清楚的长期副作用.
- 新兴证据表明,失调的刺激/抑制 (E/I) 平衡,特别是涉及GABAergic信号传递,在ADHD病理生理学中起着至关重要的作用.
研究的目的:
- 审查GABAergic功能障碍在ADHD病理生理学中的作用.
- 探索GABAergic内部神经元通路中的潜在药理标,用于ADHD治疗.
- 讨论对具有特定并发症和症状领域的子群体的影响.
主要方法:
- 审查当前的临床证据和关于ADHD中E/I平衡的新兴研究.
- 来自全基因组关联研究 (GWAS) 的研究结果分析,将GABA基因与ADHD联系起来.
- 检查与GABAergic功能障碍相关的ADHD遗传小鼠模型.
主要成果:
- 遗传研究和小鼠模型突出显示了ADHD群体中GABA相关基因的突变.
- GABAergic内部神经元功能障碍越来越被认为是ADHD的一个关键机制.
- 功能障碍的GABA信号传递有助于ADHD中观察到的E/I不平衡.
结论:
- GABAergic功能障碍是ADHD病理生理学的重要因素.
- 针对特定的GABA受体和蛋白质为ADHD亚群提供了一个有希望的治疗途径.
- 这种方法可以为那些对兴奋剂无反应或患有特定并发症的患者提供替代治疗方法.
更多相关视频
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
相关概念视频
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
